Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response

Figure 5 Inhibition of interleukin-6 reduces the migration and invasion of drug-resistant non-small cell lung cancer cells under cisplatin treatment. A: Cells in each group were treated with cisplatin (DDP; 20 μmol/L), and a transwell assay was applied to detect the cell invasion; B: The cells were treated with the DDP (20 μmol/L), and a scratch assay was adopted to assess the migration rate of cells; C: Representative images of scratch assays performed at 0 hour and 24 hours to evaluate the migration of A549, A549/DDP, SK-MES-1, and SK-MES-1/DDP cells under DDP ± tocilizumab treatment; D: Quantification of cell migration rates from panel C. Data were presented as mean ± SD (n = 3). ^aP < 0.05, ^bP < 0.01 vs A549 or SK-MES-1; ^cP < 0.01 vs A549/DDP or SK-MES-1/DDP. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. DDP: Cisplatin; TCZ: Tocilizumab.